These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 32626773

  • 1. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
    Chen D, Sun X, Zhang X, Cao J.
    Biomed Res Int; 2020; 2020():9525207. PubMed ID: 32626773
    [Abstract] [Full Text] [Related]

  • 2. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y, Li T, Assani G, Ling H, Zhou Q, Zeng Y, Zhou F, Zhou Y.
    Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
    [Abstract] [Full Text] [Related]

  • 3. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 4. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T, Xiong Y, Wang Q, Chen F, Zeng Y, Yu X, Wang Y, Zhou F, Zhou Y.
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [Abstract] [Full Text] [Related]

  • 5. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
    Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ.
    Cancer Lett; 2018 Mar 28; 417():131-140. PubMed ID: 29306020
    [Abstract] [Full Text] [Related]

  • 6. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G, Schmitz S, El Baroudi M, Caignet X, Pyr Dit Ruys S, Roger PP, Vertommen D, Machiels JP.
    Mol Cancer Ther; 2020 Mar 28; 19(3):777-789. PubMed ID: 31924739
    [Abstract] [Full Text] [Related]

  • 7. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.
    Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King FJ, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris JL, Mossé YP.
    Clin Cancer Res; 2017 Jun 01; 23(11):2856-2868. PubMed ID: 27986745
    [Abstract] [Full Text] [Related]

  • 8. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
    Tripathy D, Bardia A, Sellers WR.
    Clin Cancer Res; 2017 Jul 01; 23(13):3251-3262. PubMed ID: 28351928
    [Abstract] [Full Text] [Related]

  • 9. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK.
    Oncotarget; 2017 Jul 04; 8(27):43678-43691. PubMed ID: 28620137
    [Abstract] [Full Text] [Related]

  • 10. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
    Wang D, Bao H.
    Cancer Chemother Pharmacol; 2022 Jan 04; 89(1):31-40. PubMed ID: 34655298
    [Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma.
    Wong CH, Ma BBY, Hui CWC, Lo KW, Hui EP, Chan ATC.
    Sci Rep; 2018 May 22; 8(1):8010. PubMed ID: 29789630
    [Abstract] [Full Text] [Related]

  • 12. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein Kinase 1α-Dependent Inhibition of Wnt/β-Catenin.
    Cui L, Zhao J, Liu J.
    Am J Med Sci; 2018 Mar 22; 355(3):274-280. PubMed ID: 29549930
    [Abstract] [Full Text] [Related]

  • 13. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
    Kim JY, Jayne LA, Bai Y, Feng MJHH, Clark MA, Chung S, W Christman J, Cianciolo RE, Pabla NS.
    Biochem Pharmacol; 2020 Jul 22; 177():113939. PubMed ID: 32229099
    [Abstract] [Full Text] [Related]

  • 14. Targeting CDK4/6 in patients with cancer.
    Hamilton E, Infante JR.
    Cancer Treat Rev; 2016 Apr 22; 45():129-38. PubMed ID: 27017286
    [Abstract] [Full Text] [Related]

  • 15. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD.
    PLoS One; 2021 Apr 22; 16(6):e0252927. PubMed ID: 34138895
    [Abstract] [Full Text] [Related]

  • 16. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Burris HA.
    Expert Rev Anticancer Ther; 2018 Mar 22; 18(3):201-213. PubMed ID: 29457921
    [Abstract] [Full Text] [Related]

  • 17. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
    Aristizabal Prada ET, Nölting S, Spoettl G, Maurer J, Auernhammer CJ.
    Neuroendocrinology; 2018 Mar 22; 106(1):58-73. PubMed ID: 28226315
    [Abstract] [Full Text] [Related]

  • 18. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM, Zangardi ML, Moy B, Bardia A.
    Oncologist; 2017 Sep 22; 22(9):1039-1048. PubMed ID: 28706010
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
    Cao J, Sun X, Zhang X, Chen D.
    Clin Transl Oncol; 2018 Jun 22; 20(6):761-767. PubMed ID: 29086249
    [Abstract] [Full Text] [Related]

  • 20. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X, Hong Y, Mao Y, Chen N, Wang Q, Wang Z, Zhang L, Wang L, Shi C, Shi W, Ge H, Li A, Li X, Xia G, Liu Y.
    Cancer Sci; 2020 May 22; 111(5):1761-1773. PubMed ID: 32103527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.